Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) – Research analysts at SunTrust Banks increased their Q3 2017 earnings per share (EPS) estimates for Tetraphase Pharmaceuticals in a report released on Thursday. SunTrust Banks analyst E. Nash now forecasts that the biopharmaceutical company will post earnings per share of ($0.61) for the quarter, up from their prior estimate of ($0.77). SunTrust Banks also issued estimates for Tetraphase Pharmaceuticals’ Q4 2017 earnings at ($0.46) EPS, FY2017 earnings at ($2.62) EPS, FY2018 earnings at ($1.61) EPS, FY2019 earnings at ($1.42) EPS, FY2020 earnings at ($0.28) EPS and FY2021 earnings at $1.07 EPS.

Other equities analysts have also issued research reports about the company. BMO Capital Markets reissued a “buy” rating and issued a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Friday, May 5th. Stifel Nicolaus raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the company from $8.00 to $15.00 in a research note on Wednesday, July 26th. HC Wainwright initiated coverage on Tetraphase Pharmaceuticals in a research note on Tuesday, July 11th. They issued a “buy” rating and a $15.00 target price on the stock. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Thursday, July 27th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $10.25.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/07/equities-analysts-set-expectations-for-tetraphase-pharmaceuticals-inc-s-q3-2017-earnings-nasdaqttph.html.

Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at 5.655 on Monday. The company has a 50-day moving average price of $7.40 and a 200-day moving average price of $6.92. Tetraphase Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $9.93. The stock’s market cap is $288.70 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.07. The company had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.47) EPS.

Several large investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP raised its stake in Tetraphase Pharmaceuticals by 90.2% in the fourth quarter. GSA Capital Partners LLP now owns 33,600 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 15,931 shares in the last quarter. Wade G W & Inc. acquired a new stake in Tetraphase Pharmaceuticals during the first quarter worth approximately $138,000. Teza Capital Management LLC raised its stake in Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,281 shares in the last quarter. Citadel Advisors LLC raised its stake in Tetraphase Pharmaceuticals by 18.6% in the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 2,496 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Tetraphase Pharmaceuticals during the fourth quarter worth approximately $156,000. 45.48% of the stock is currently owned by institutional investors.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.